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The rsfety and efficacy of B IO- to IS-mglh coniinuous infusion of 
inlravenous diltiaxem were evaluated in 47 paiients with alrial 
hbriUal#un w flutter who first responded to 20 mg ur 20 mg 
followed by one or mure 25mg bolw doses of open label intrave- 
“ow diltiazem. Of the 47 patients, 44 respuuded to the h&s 
iqjectiou end were randomized under double-blind condilions to 
receive either B runtinuuu.sialustun of inlrwenuus diltiszem (IDlo 
15 mh) (23 ~alienlrl or dacrbn I21 oatients) for UD to 24 h. 
&e&n~74%) 6f thi23 pa&s driving dill&u infusian 
and nune of the 21 wilh plucrho infusian maintained B iherapeutic 
rapunw fur 24 h (p c O.Wlh Over 24 h. p~lienb receiving 
dtldazem infusion lost ressponre significantly more slowly than did 
tbmerecelvingplacebu Inksion (PC 0.001 j. Nonrespancfers to the 
duubk-blind iafusion were dven an additional tmlus iniection of 
opera MeI lntrweuuur dtltbku and admluirtrrfd 8” ipen label 
24-h inlraveaous dilltazem inrusion. The overall pmporlion al 
pplieats maintaining a response to a 24-h infusion of intravenous 
Diltiazem is a calcium channel blocking agent that has been 
used for the treatment of aogma pectoris and systemic 
hypertension (1.21. It has been shown to have chronotropm 
and dromotropic effects (3) and on the basis of these elec. 
twphyriologic properties. intravenous and oral diltiazem 
have been used for the short- and long-mrm treatment of a 
variety of supravtntticular arrhythmms (4-l I). 
Atrial fibrillation and arrial Rutter are common susrained 
arrhythmias occurring in patients with cardiac and pulmo- 
nary disease (II). lo some patients with these arrhythmias. 
the ventricular response may be rapid and accompanied by an 
exacerbation of angina or heart failure. An iatwenous dl- 
tiazem infusion that is safe and achieves rapid reduction of 
dittiazem under double-blind or open label conditions combined 
WIE 83$5 134 0r 41). 
Efficacy of the 24-h infuston of inlravenous dilttarem was 
similar in elderly versus young patients, those who did versus 
lhme who did not rewiw digoxta and th.w weigh& <ti4 wsus 
284 kg. Aowrer, intrarenous diltianm apptwed ta be more 
e&ciive in atrial fibrillation lhae in atriat Rutter. An significant 
untoward effects were u&d. 
A b&s dose or doses folkwed by a 24-b continuous infusion of 
intravenius diltimem can be safely administered to palients with 
atria1 fibrillation or flutter and can rapidly nod efkttvely &dew 
and maintain heart rate controt in mart patients. lniravrr!~w 
dilliazem can serve as B tberapculic bridge ia patt@nlcj wttb thesz 
atrial arrhythmias awaiting initiation or onset of action of long 
term antiarrbgtbmtc tberap)- or cardiorerslon. 
(I rlnr cou C&~-I f997ds:a91-7r 
ventricular response would be useful before initiation of defin- 
itive antlarrhythmic therapy or electrical cardioverrion to stnus 
rhythm. The purpose of this multicenter investigation (see 
Appendix) was to demonstrate the safety and efficacy cf a 
continuous intravenous diltiazem infusion for 24.h heat? rate 
cantrol in patients with atrial fibrillation or flutter. 
Methods 
The protocol was approved by the Investipticnal Review 
Board at each of the five participating medical centers (see 
Appendix). Each pallent gave witten informed consent 
before entry mm the study. F’atieuts were enrolled in the 
study between August 1987 and October 198% 
Study patients. Patients were included in this study if 
they wcrc >t8 years of age and had established atrial 
fibrillation or atrial flutter with a duration ~24 h. The 
ventricular %e fdocumented by electrocardiogram [ECGI) 
had to be ~120 beats/min over a 15-min baseline period before 
the study dtug was given. Atrial fibrillation was defined by the 
absence of discrete regular atrial activity; atrial flutter was 
dmpmd by Ihe presence of discrete flutter waves. 
E.~chsion criteriu included severe cangesrive heart fail- 
Figure 1. Flow chart of the study de- 
sign. I.V. = infravenvu5. 
ure iNew York Hean Association class 111 or IV). history of 
sinus node dysfunction. second- or third-degree alriovcn~ricu- 
lar(AVI block. Wol&Parkinzon-While syndrome. hypotension 
with a systolic blood pressure 40 mm Hg. history of allergy or 
idiosyncratic reaction to diltiazcm. clinrcally significant abnor. 
malirics ofolher organ systems or muitifocal alrial tachycardia. 
Nocalcium channel blocking qenls. lype IA or IC anliarrhyth- 
mic agenls (for example. quinidine, procainamide. flccainidc. 
encninide). amiodarone or a beta-adrcnergic blocking agenl 
was given within 5 elimination half-lives before administration 
of the study drug. Patierus who received digoxin preparalions 
before study entry were not excluded provided the dosage was 
constant over the preceding I week and they had no evidence 
of digitalis intoxicar;on. 
Sindy design IFig. I). This was a randomized. double- 
blind, parallel, placebo-controlled study. Before entry into 
the study. a medical history was taken and a physical 
examination performed. If the baseline ECG continued 
(~15 min) to confirm the presence of atrial fibrillation or 
flutler with a mean ventricular rate a 120 beatslmin. the 
patient was given a 20-mg bolus dose of open label intrave- 
nnus diltiazem over 2 min (drug period I). Patients who did 
nol have a therapeutic response. defined as a decrease in 
heart rate IO <IO0 bentsimin. ~213% decrease in heart rate 
from baseline or conversion to normal sinus rhythm within 
I5 min. were given a second 25-mg bolus dose of intravenous 
diltiazem over 2 min and monitored again for a therapeutic 
response river the nexl IS min. Patients who did not have a 
satisfactory therapeutic response to either dose were entered 
into the postsludy phase. 
fnf;enrs rlhJ hid <I tlrmrpclrfir rPipo!lw rllrrrr?~ dmg 
period I received under double-blind conditions a 24-h 
continuous infusion of intravenous diltiarcm or placebo at a 
rate of IO mgih (drug period II). An increase m the infusion 
ratr from IO to IS mgih was permItred al any Lyme li lhe 
patient lost response while receiving the IO-mg!h iniu&n. 
An increase in the infusion rale from IO to I5 m!$h wah 
permitted before 4 h If response was mamtained ‘our a further 
reduction in heart rate was desired. Parients were observed 
every 30 min for a therapeutic response while at rest for 
25 min. Heart rate and rhythm were obrained from I-min 
ECG rhythm strips. Hear! rate was also obramed from a 48-h 
Halter monitor. 
Porienrs were considerrd ro knw nwinraracd o hropeu- 
iic respunw finfkzn rrspondwr) if respou\e was not lost 
during the 24-h double-blind infusion (drug period 111. They 
were considered to have failed to maintain a therapeutic 
response to drug infusmn (infusion nonresponders) if re- 
sponse was lost over two ccmsecuwe ewduatmna \paced 
30min apart while they were receiving the IS-mgh infw.ion 
in drug period II. Infusion nonresponders in drug period II 
were given an additional 20 mg lor 20 mg followed by ?5 mg) 
of intravenous diltiazem (drug period lltl and then received 
an open label continuous infusion of intravenous diltiazem at 
the rate of IO mgih (drug period IV). which could also be 
increased to 15 mgih. Response to open label infusion of 
intravenous diltiazem in drug period IV was defined in a 
manner similar to that in drug period II. If response was not 
lost at the end of 24 h in drug period II or IV. rhe intravenous 
infusion of diltiazem was stopped and patients entered a IO-h 
washout period. Subsequent therapy for atrial fibrillation or 
flutter was al the discretion of each patient‘s physician. 
Data analysis. Analysis of efficacy used Ihe intent to treat 
principle. which included all randomized patients. The prl- 
mary response variables used to determine efficacy were the 
maintenance of therapeutic response (yet or no) and the 
duration of therapeutic response (hours1 in drug period Il. 
Kaplan-Meier survival estimates were plotted to visuatly 
compare the two treatment groups with respect to the 
duration of therapewc response. The Cox proportional 
hazards model was then used to tebt whether pnticms 
receiving diltiazem maintained therapeutic response as long 
as patients on placebu. Maintenance ot’ the response to 
diltiazem and placebo was compared with tbe Mantcl- 
Haenszel test. The treatment comparison for both the Cou 
model and the Mantel-Haensrel procedure wh ddjusled for 
investigative site. 
Subgroup analyses of the duration of rherapemic rc- 
sponse and maintenance of therapeutic respond during drug 
periods II and 1V were considered for patients b\ho had atrial 
fibrillation versus atrial flutter. wrc <hC verw ~65 years 
of age, weighed <&I verw ~84 kg and receiwd or did not 
receive digoxin. Clrnicdl variable\ arc prewnled a~ medn 




Clinical character&x Forty-scxn patxnts entered Ihe 
study and rrceivcd a bolus dose or doses ofdilriarem in drug 
period I. ‘Thirty-ww pwented whh arnal fibrdlalion and 
IO with atrial flutter. Fofiy-four of rhc 47 patients \&ho 
rccwed dn open label bolus dose of diltiazem were classi- 
fied aa bolux rewelders and were randomized in drug period 
II of the study. These 44 randomized paricnis comprised 36 
patient\ with alrid fibrillation and 8 r*ith atria1 Rulter. The 
ctinical churaclcristics of the patients receivingdiltiazem and 
plxebo infusion in drug period II uere similar ‘Tsble Il. 
Bolus dose or doses. In drug period I. 44 (947~) of 47 
patient> responded to intravenous dihiazem (36 lY77cl of 37 
wth atrial fibrillation and 8 [so%] ofthosc Gth atrial flutterl. 
Forty-three pmients responded to the 2O-mg dose of dil- 
tiarem and one pattent responded to the 2%mg dose after 
receiving the 20.mg dose. Three patients drd nof respond Io 
the 5mp dose after receiving the 20.mg dose and were 
entered mto the poststudy phase. Of the 43 responders to the 
ZO-mp doac. 3 received the ?S-mg dose of intravenous 
dihiarem for further heart rate reduction afmr having met 
rcsponsc crlreria. Response occurred in a mean time of 4 ? 
4 min. timed from the beginning of the !-min bolus dose in 
rhe 44 patienrc who responded to intravenous diltiazem. Tit: 
mean baseline heart rate for the 43 bolus responders and 4 
bolua nonre$punders to the ?O-mg dose ~;f inlravenous dil- 
GaLem was I3 I and 129 beatslmin. respcc~~vcly (p = NS). At 
? mm after admtmrtration ofthe 10.mg dobe of diltiazcm. the 
mrrn hear! rate ~&as reduced by 17% ir. .dl patients. by l95? 
in bolus responders and by only 45: m bolus nonrenponderh. 
Heart rate at 7 LO I7 min was still reduced in bolus rzspond- 
crs and \~a% littlc changed in bolus nonre?ponders. In seven 
patients who receiwd the !.F-mg dose (after the IO-mg dose1 
Figure 2. Kaplan-Meier eslimales for the proportion of 
all randomized patients receiving diltiazem or placebo 
infusion whose response was maintained during drug 
periad II. Numbers in parentheses indicate the number 
of patients with a response during the time interval. 
reduclion. the mean baseline hean rate for four 501~s respond- 
crs and three bolus nonrespondcn was 132 and 131 beatsimin. 
respecrivcly (p = NSI. Two minutes after the administration of 
the 25.mg bolus dose of diltiazem, the mean heart rate was 
reduced by 17C/oinallpatients. by3tEZ in four bolus responders 
and by only 5% in three bolus nonresponders. 
Maintenance infusion. Forty-four patients entered the 
double-blind part of this study (drug period II). Twenty-Three 
patients were randomized to receive the diltiazem infusion 
and II to receive the placebo mfusion. During the 24 h of 
infusion. the mean (2 SD) time of admini>tration of the 
IO-mglh dose of diltiarcm was 11.4 ? 10.4 h. In those 
patients who were receiving the IO-mgPn dose and later 
received the l5-mdh dose. the mean (2 SD) time of admin- 
istration of the IS-mglh dose was 14.2 I?: 9.4 h. 
Seventeen (74%) of 23 patients receiving a maintenance 
infusinn of intravenous diltiazom and 0 of 21 patients receiv- 
ing a maintenance infusion of placebo maintained response 
during 24 h nf drug period II (p < O.WII (Fig. 21. In drug 
period 11. the rate at which patients receiving diltiazem 
infusion lost response was significantly slower than the rate 
at which those with placebo infusion lost response (p < 
O.OOlL The estimated hazard ratio (diltiazemiplacebo) from 
the Cox model WE 0.132 (95% confidence limits 0.047. 
0.37lJl. No patients who received diltiazem infusion lost 
therapeutic response after 5 h. whereas no patients receiving 
placebo infusion maintained a therapeutic response after9 h. 
Figure 3 displays the mean percent change in heart rate from 
baseline in drug period II (24 h) in patients given diltiazem 
(including both responders and nonresponders to diltiazem) 
and patients given placebo. 
In the patients receiving diliiazem who mamtained re. 
spense for 24 h during drug period II, there was a marked 
(31%) decrease in heart rate by I h. Thereafter, the heart rate 
decreased gradually over the remainder of the 24 h (Fig. 4). 
The mean percent decrease in heart rme from baseline was 
34%at3h,37%a~5h.38%allOh.44%at15h,44%ai20h 
and 40% at 24 h. 
Hem mm dara obtained in poticnts given pbceho infic- 
sion allowed determination of the duration of response to 
one or more bolus doses of intravenous diltiazem in patients 
who responded to bolus administralion of diltiazem. The 
estimated IOth, 50th (median) and 90th percentiles for the 
duration of response in these patients were 1.8.3.5 and 8.4 h, 
respecrively. 
The uverall propurrion of patients given diltiazm infit- 
sion who maintained response in drug period II or IV 
(double-blind or open label parts of the study) was 83% (34of 
41). Four of the 41 patients had received diltiazem during the 
double-blind and npcn label infusion parts of the study. Two 
of these four patients responded to the open label infusion of 
dilriazem but are no! included as overall responders to the 
intravenous diltiazem infusion. The proportion of respond- 
ers was similar in the elderly (~65 years) versus the young 
(~65 years), among those who did versus those who did not 
receive digoxin and among those with a low 1184 kg) versus 
a high (84 kg) body weight. However. the percent of 
patients whh atrial fibrillation who responded to intravenous 
dilriazem ww greater than lhal of patients with atrial flutter 
(Table 2). 
Figure 3. Time course of hean rale response to placebo and 
diltiazem (23 responders and 20 nanresponders) during drug period 
If (mean values f SD). The mean baseline heart rate for placebo- 
treated and dihiazcm-treated palients was 130 and 132 beatsimin. 
xswctively. ID) on the x axis denotes the last heart rate before the 
startofinfusion. Patient numbersdecreareovertimeas patientslose 
resp~nsa and are entered into drug period III. 
The type of response durmp double-blind or upcn tbcl 
infusion parts of the study (drug periods II and IV. rerpec- 
tivelyt tn the majority of diltiazem infuston rrsponderh 
consisted of both a heart rate <lo0 beatc!min and a e?OG 
decrease in heart rate from baseline. No patient had conver- 
sion IO sinus rhythm (Table 3). 
Washout of infusion. The 34 patient\ who mamtained 
rerponae to a 24-h infusion of intravenous diltiazem during 
either the double-blind (drug period II) or the open label 
infusion part of the study (drug perad IV) entered the 
washout period. The mean heart rate measurements taken at 
I, 3.5 and 10 h from the end oithe 24-h mfusion were 81. X7. 
94 and 107 beats/mitt. respectively. The percent of intrave- 
nous diltiazem infusion responders who maintained reqxmsc 
during the IO-h washout period steadily declined from 94% at 
1 h to 53% at 10 h. Nine (26%) diltiazem infusion responders 
had received additional antiarrhythmtc therapy during the 
washout period. 
Table 2. Proportion of Diltiazem lnfus~on Responders During the 
Double-Blind nnd open Label lnfur~on Pkrts of the Study 
Combined (drug periods II and IV. rcspcct~vcl~‘~ 
S:mptum r,aluation. S>mptoms were evaluated before 
tat hawlinut and on completion of the study. Cf the 34 
patient% a ho rcwonded to ihe doublf-blind or open label 
infusion nf intrarenous diltiarem. IS noted a Icsxning of 
qmptom5 of p~ilpttatton. dizzmess or weahncrs from the 
hasrlinu p&d. Nine patients did not note a change m 
k)mptom~ and in ttl patients. symptoms were not prerrnt or 
not awswd. Oirhe seven paticnls uho did nut respond to 
intrwwuus diltiaxm donng the double-bhnd or open label 
infusiun. four noted a decrease in xymptomn and three noted 
no change. 
Subsequent therapy. Forty-one of the 17 patients who 
entered the study were given other antiarrhythmic therapy 
for cnntrol or prophylaxis of the arrhythmta during the 
postwdy phase. The majonty of patienls received oral 
diltiarcm 115 patients) and mtravenous or oral digoxin (15 
patxntst. 
Blood pressure. Bcforc administration of bolus doses of 
iotrwenou~ dilttazem. the mean baseline systolic and dias- 
tohc blood prewre was I28 2 20 and 83 -r I! mm Hg. 
respectively hr ! mitt after the !O-mg bolus dose of dil- 
tiaxm. there was a significant (p 4 O.OOI) decrease from 
bmeltne in mean systolic and diastolic blood pressure in bath 
bolus responders and nonresponderc (by I3 2 17 and 10 f 
I? mm He. respectively). 
l,rwrt~rlirrrrl\- bc+ru imfirllir)rl q)” Ncrbrlennrrte injksion 
d o,lro ~r~lrrrinisrrrtrir)ft r$ ow 0F mow ho/w rltaer rd 
diiricr;w~. mean systolic blood pressure was reduced from 
baseline by I2 7 I4 and I I 2 IX mm Hg tp = 0.733) and 
mean diaMtc htood pressure by I I i I.3 and 8 ? 12 mm Hp 
tp = 0.446) in the diltiazem and placebo infusion f!roups. 
rc\pcct.vcly. During maintenance infusion. the reduction 
from hureline in mean \ybtolic and dinstotic blood pressure 
r.mged from Y z !O to 15 ? 19 mm Hg and 8 2 IO to IO = 
I5 mm Hgm the dlltt;tzem-‘reatedpaticnts. respecttvely.and 
from 0 to J z I6 mm Hg and 2 f .i to 3 k 1 I mm Hg in the 
Table 3. Type of Response (no. of patients) in 34 Diltiazem Infusion Rerpondcrs During Drug 
Periods II ad IV 
Time Ihi 
placebo-treated patients. respectively. There was no differ- 
ence in systolic and diastolic blood pressure in the respond- 
ers and nonresponders to diftiazem infusion. 
Digoxia. Thirty-two patients (I6 each in the placebo and 
diltiazem infusion groups) had received digoxin within 5 
half-lives before receiving intravenous diltiazem in drug 
period I. No patient who had received digoxin had an 
elevated plasma digoxin concentration or exhibited signs or 
symptoms of digoxin toxicity. Prestudy plasma digoxin 
concentrations were similar in the two infusion groups 
lplacebo 0.71 * 0.36 ngiml; diltiazem 0.73 t 0.25 “g/ml; 
therapeu.ic range 0.9 to 2. I: p = NS) and did not appreciably 
change from prestudy to poststudy (placebb~0.65 i 
0.24 @ml; diltiazem 0.78 ? 0.33 @ml). 
Adverse events. There was no death, prolonged hospital- 
ization. permanent disability or dosage reduction as a resulr 
of an adverse event. Significant side effects included hypo- 
tension in two patients: one patient was quadriplegic (base- 
line blood pressure I IO/60 mm Hg). Thirty-seven minutes 
after initiation of the placebo infusion. the patient experi- 
enced lightheadedness and slight tightness in his chest. His 
systolic blood pressure at the time was 80 mm Hg (diastolic 
blood pressure was not obrained). The placebo infusion was 
discontinued and the patient was treated with normal saline 
solution. He recovered in 2.5 h with a blood pressure of 
%/ho mm Hg and had no sequelae. One patient (baseline 
blood pressure I IO/70 mm Hg) received 50 mg of captopril 
1.5 h afler initiation of the IO.mgih infusion of diltiazem. AI 
3 h of infusion, rhe patient developed hypolension 
lSOi6O mm Hg). The dikiazem infusion was discontinued and 
the patient was treated with normal saline solution. The 
patient recovered in I3 min with a blood pressure of 
9916-l mm Hg and had no sequelae. 
Discussion 
Efficacy of intravenous diltiazem in atrlal Abrillation and 
Auller. In this study, a 24-h continuous infusion of intrave- 
naus diltiazem (10 to I5 mgih) given after a bolus dose (20mg 
alone or 20 mgfollowed 15 min later by 25 mg) was safe and 
effective treatment for control of heart rate during atrial 
fibrillation or atrial flutter in 83% of patients. Efficacy with 
the 24-h infusion of intravenous diltiazem was similar in 
elderly versus young patients, those who did versus those 
who did not receive digoxin and those weighing ~84 versus 
284 kg. However, intravenous diltianem appeared to be 
more effective in patients with atrial fibrillation than in those 
with atrial flutter. With this regimen of diltiazem bolus and 
maintenance infusion. heart rate was controlled within ap 
proximately 4 min and control was maintained for 24 h. After 
the infusion was stopped, heart rate remained well con- 
trolled in about 50% of lhe patients for up to 10 h. 
Study limitntions. Our study has potential limitations. We 
could not determine if dilriazem prolonged the duration of 
atrial fibrillation or atrial flutter because the duration of 
the study was approximately 48 h. We did not include 
patients with class III or IV heart failure or hypotension 
1190 mm Hg). 
Comparison with previous investigations. There have 
been no studies of intravenous diltiazem administered as a 
24-h infusion for heart rate control in patients with attial 
fibrillation or alrial flutter. Previous investigations (6-10) 
have shown that a bolus dose of intravenous diltiazem 
generally administered over 2 min promptly reduces the 
rapid ventricular rate in patients with airial fibrillation or 
flutter; the duration of response has been reported (8) to 
range between I and 3 h. In our study, the response IO a 
bohts dose or doses of intravenous diltiazem was rapid 
(within minutes of the bolus ittjeftion) and the median 
duration of response tothe bolus dose was 3.5 h. It would be 
desirable IO maintain control of the ventricular rate over an 
extended period of time. Prompt and sustained rate control 
with intravenous diltiazem may have improved cardiac he- 
modynamics and symptoms of angina or heart failure, which 
may also have contributed to the heart rate slowing we 
observed over 24 h with this infusion. 
Comparison of intrttvenotts dMwttt and other intrave. 
nous agents that lower heart rate. In this study, we did not 
compare intravenous diltiazem with other intravenous anli- 
arrhythmic agents that slow ventricular rate in atria1 fibril- 
lation or flutter, such as beta-adrenergic blocking agents, 
digoxin or verapamil. Ezmolol. a new beta-blocker, was 
shown to be elfective for slowing heart rate in atriaI fibrllla- 
tion (13-15); however. dose titration with esmolol freouentlv .~ , 
resulted in a high incidence of symptomatic hypotension 
(13). Digoxin can decrease the ventricular response in atria1 
fibrillation or atrial flutter without causing hypotension, but 
its rate of onset is typically slow, and it has not been shown 
to result in conversion of atrial fibrillation to sinus rhythm 
116). intravenous vempamil may be mnre likely than dil- 
l&em to cause or exacerbate heart failure because vera- 
pamil has a greater negative inotropic effect than does 
diltiarem (17). In addidon. vewpamil ha\ nor been rested 
under controlled condilions PI a suswmed mfusion m pd. 
tients with atrial fibrillation or flutter. 
Conversion to sinus rhythm. ConverGan of ariai fibrilla- 
tion or flulter to Gnus rhythm IS a more U&III out~omc rhan 
a reduction in ventricular rate. However. normal Gus 
rhythm is often difficult to achiue or milmtain in many 
palients with atrial fibrillation or flutter, r\ho have impeircd 
left ventricular function. enlarged atria or a long duration ul 
the arrhythmia. Class IA and clabs IC aniiarrhythmic agcnta 
are useful for converting atria1 fibrillation 3r flutter to sinus 
rhythm. but their onset is &JW and their efficacv for conver- 
sion is not high. In addition. class IA agems may cauw 
significant hypotension when administered intravenou4y 
and their parasympatholytic effects may lead to an accelw 
aiion of the ventricular rate during trealmenr of atria1 Rbril- 
lation or flutter. In a recent analysis I IXI of mulrlple trial> of 
quinidine given IO maimsin smw rhythm after dwxt current 
cardioversion of atrial fibrillation. 50% of patient5 main- 
tained sinus rhythm al l? months. However. this result WI 
atrained at the price of a threefold increased inc~dsnce of 
cardiac death. Class IC agems such as Recainide and encain- 
ide are restricted to paticntr wirborrr strustur~l hwrt discax 
because of their high incidence of ser~ow proarrhythmia ;and 
are comraindicated when rhe rjecrion fnxtion i$ low or hear, 
failure. or both. 1s present (W-21). The beneiirb ot’ma,nra,n- 
ing sinus rhythm in a given patient m&t hc wclghcd agiun~l 
the risk of proarrhythmia. drug side ctfects and pat&r 
intolerance ol the medical regimen. 
Conclusion 
601~s doses (20 mg. 25 mg) followed b!y a 24-h contmuou~ 
infusion of intravenous diltiazem (IO to I5 mg/hl can bl: 
safely administered to patients with atrial fibrillation or 
Rotter and can rapidly and ekaively achieve and maintain 
heart rate control in marl patients. IntravrnouF diltiatem ha\ 
applicability as a “therapeutic bridge” in patienta wrth thehe 
atria1 arrhythmias awaiting initiation or onxt of actron of 
long-term antiarrhythmic therapy or cardioversion. 
Appendix 
The lnlravenous Diltiazcm Arriul Fibrillntion/-\(rial Flmtcr 
Study Group 
